Peter Edward Fecci

Fecci

Professor of Neurosurgery

As the Director of both the Brain Tumor Immunotherapy Program and the Center for Brain and Spine Metastasis at Duke University, I focus our programmatic interests on the design, optimization, and monitoring of immune-based treatment platforms for patients with intracranial tumors, whether primary or metastatic. Within this broad scope, however, my own group looks more specifically at limitations to immunotherapeutic success, with a particular focus on understanding and reversing T cell dysfunction in patients with glioblastoma (GBM) and brain metastases. We employ a systematic approach to categorizing T cell dysfunction (Woroniecka et al, Clin Cancer Res 2018 Aug 15;24(16):3792-3802), and whereas our earlier work addressed concerns for regulatory T cell-induced tolerance, we now heavily study T cell ignorance and exhaustion, as well. Regarding the former, we recently published the novel phenomenon of S1P1-mediated bone marrow T cell sequestration in patients with intracranial tumors (Chongsathidkiet et al, Nat Medicine 2018 Sep;24(9):1459-1468). Regarding the latter, we have likewise recently identified and characterized exhaustion as a significant limitation to T-cell function within GBM (Woroniecka et al, Clin Cancer Res 2018 Sep 1;24(17):4175-4186). I very much look to collaboratively integrate our approaches with others investigating innovative treatment options. I continue my focus on combining strategies for reversing T cell deficits with current and novel immune-based platforms as a means of deriving and improving rational and precise anti-tumor therapies. It is my sincerest desire to forge a career focused on co-operative, multi-disciplinary, organized brain tumor therapy. Ultimately, my goal is to help coordinate the efforts of a streamlined and effective center for brain tumor research and clinical care. I hope to play some role in ushering in a period where the science and treatment arms of brain tumor therapy suffer no disjoint, but instead represent the convergent efforts of researchers, neuro-oncologists, medical oncologists, radiation oncologists, biomedical engineers, and neurosurgeons alike. I hope to see such synergy become standard of care.

Appointments and Affiliations

  • Professor of Neurosurgery
  • Associate Professor of Biomedical Engineering
  • Associate Professor in Immunology
  • Professor in Pathology
  • Member of the Duke Cancer Institute

Contact Information

  • Office Location: 201 Sands Bldg., Box 3050, Durham, NC 27710
  • Office Phone: (919) 681-1010
  • Email Address: peter.fecci@duke.edu

Education

  • Dana-Farber Cancer Institute, 2012
  • Massachusetts General Hospital, 2013
  • Massachusetts General Hospital, 2008
  • Ph.D. Duke University, 2007
  • M.D. Duke University School of Medicine, 2007

Research Interests

Brain Tumor Immunotherapy
Cancer-Induced Immune Dysfunction
Glioblastoma
Brain Metastasis

Awards, Honors, and Distinctions

  • Paper of the Year. American Association of Physicists in Medicine. 2017
  • Visting Scholar. National Institutes of Health. 2017
  • Duke Health Scholars Award. Duke University School of Medicine. 2016
  • Prince Mahidol Youth Mentor Award. Prince Mahidol Award Foundation. 2016
  • Alpha Omega Alpha. Alpha Omega Alpha Medical Honor Society. 2015
  • Resident Advocate Award. Duke University Department of Neurosurgery. 2015
  • Sontag Distinguished Scientist Award. Sontag Foundation. 2015
  • Matson Award for Best Basic Science Research. New England Neurosurgical Society. 2013
  • Preuss Award for Neuro-Oncologic Research. Congress of Neurological Surgeons. 2013
  • NIH Loan Repayment Program Award. National Institutes of Health. 2011
  • Resident Teaching Award. Tufts University School of Medicine. 2008
  • Neurosurgery Award. Duke University Department of Neurosurgery. 2007
  • Keynote Speaker. Society for Neuro-Oncology. 2006
  • Eugene A. Stead Scholar. Duke University School of Medicine. 2001
  • Medical Scientist Training Program Fellowship. National Institutes of Health. 2001
  • Cornell-Diamante Scholarship. Cornell University. 1999
  • Merrill Presidential Scholar. Cornell University. 1999
  • Nanaline H. Duke Scholar. Duke University School of Medicine. 1999

Courses Taught

  • MOLMED 301B: Research in MOLMED - Oncological Sciences
  • NEUROSCI 493: Research Independent Study 1
  • NEUROSCI 494: Research Independent Study 2
  • PATHOL 293: Research Independent Study
  • PATHOL 793: Research Independent Study

In the News

Representative Publications

  • Shen, SH; Woroniecka, K; Barbour, AB; Fecci, PE; Sanchez-Perez, L; Sampson, JH, CAR T cells and checkpoint inhibition for the treatment of glioblastoma., Expert Opin Biol Ther, vol 20 no. 6 (2020), pp. 579-591 [10.1080/14712598.2020.1727436] [abs].
  • Moravan, MJ; Fecci, PE; Anders, CK; Clarke, JM; Salama, AKS; Adamson, JD; Floyd, SR; Torok, JA; Salama, JK; Sampson, JH; Sperduto, PW; Kirkpatrick, JP, Current multidisciplinary management of brain metastases., Cancer, vol 126 no. 7 (2020), pp. 1390-1406 [10.1002/cncr.32714] [abs].
  • Kemeny, HR; Elsamadicy, AA; Farber, SH; Champion, CD; Lorrey, SJ; Chongsathidkiet, P; Woroniecka, KI; Cui, X; Shen, SH; Rhodin, KE; Tsvankin, V; Everitt, J; Sanchez-Perez, L; Healy, P; McLendon, RE; Codd, PJ; Dunn, IF; Fecci, PE, Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease., Clinical Cancer Research, vol 26 no. 5 (2020), pp. 1141-1151 [10.1158/1078-0432.CCR-18-3486] [abs].
  • Huang, M-N; Nicholson, LT; Batich, KA; Swartz, AM; Kopin, D; Wellford, S; Prabhakar, VK; Woroniecka, K; Nair, SK; Fecci, PE; Sampson, JH; Gunn, MD, Antigen-loaded monocyte administration induces potent therapeutic antitumor T cell responses., J Clin Invest, vol 130 no. 2 (2020), pp. 774-788 [10.1172/JCI128267] [abs].
  • Kirkpatrick, JP; Fecci, PE, Offer Hypofractionated SRS… If Her Performance Status Is Good., Int J Radiat Oncol Biol Phys, vol 105 no. 5 (2019), pp. 940-941 [10.1016/j.ijrobp.2018.07.001] [abs].
  • Mohammadi, AM; Sharma, M; Beaumont, TL; Juarez, KO; Kemeny, H; Dechant, C; Seas, A; Sarmey, N; Lee, BS; Jia, X; Fecci, PE; Baehring, J; Moliterno, J; Chiang, VL; Ahluwalia, MS; Kim, AH; Barnett, GH; Leuthardt, EC, Upfront Magnetic Resonance Imaging-Guided Stereotactic Laser-Ablation in Newly Diagnosed Glioblastoma: A Multicenter Review of Survival Outcomes Compared to a Matched Cohort of Biopsy-Only Patients., Neurosurgery, vol 85 no. 6 (2019), pp. 762-772 [10.1093/neuros/nyy449] [abs].
  • Fecci, PE; Champion, CD; Hoj, J; McKernan, CM; Goodwin, CR; Kirkpatrick, JP; Anders, CK; Pendergast, AM; Sampson, JH, The Evolving Modern Management of Brain Metastasis., Clinical Cancer Research, vol 25 no. 22 (2019), pp. 6570-6580 [10.1158/1078-0432.CCR-18-1624] [abs].
  • Sankey, EW; Tsvankin, V; Grabowski, MM; Nayar, G; Batich, KA; Risman, A; Champion, CD; Salama, AKS; Goodwin, CR; Fecci, PE, Operative and peri-operative considerations in the management of brain metastasis., Cancer Medicine, vol 8 no. 16 (2019), pp. 6809-6831 [10.1002/cam4.2577] [abs].
  • Liu, Y; Chongsathidkiet, P; Crawford, BM; Odion, R; Dechant, CA; Kemeny, HR; Cui, X; Maccarini, PF; Lascola, CD; Fecci, PE; Vo-Dinh, T, Plasmonic gold nanostar-mediated photothermal immunotherapy for brain tumor ablation and immunologic memory., Immunotherapy, vol 11 no. 15 (2019), pp. 1293-1302 [10.2217/imt-2019-0023] [abs].
  • Fecci, PE; Sampson, JH, The current state of immunotherapy for gliomas: an eye toward the future., J Neurosurg, vol 131 no. 3 (2019), pp. 657-666 [10.3171/2019.5.JNS181762] [abs].
  • Lorrey, SJ; Sanchez-Perez, L; Fecci, PE, Rescuing imperfect antigens for immuno-oncology., Nat Biotechnol, vol 37 no. 9 (2019), pp. 1002-1003 [10.1038/s41587-019-0248-2] [abs].
  • Choi, KJ; Ackall, FY; Truong, T; Cheng, TZ; Kuchibhatla, M; Zomorodi, AR; Codd, PJ; Fecci, PE; Hachem, RA; Jang, DW, Sinonasal Quality of Life Outcomes After Extended Endonasal Approaches to the Skull Base., Journal of Neurological Surgery Part B: Skull Base, vol 80 no. 4 (2019), pp. 416-423 [10.1055/s-0038-1675592] [abs].
  • Chongsathidkiet, P; Jackson, C; Koyama, S; Loebel, F; Cui, X; Farber, SH; Woroniecka, K; Elsamadicy, AA; Dechant, CA; Kemeny, HR; Sanchez-Perez, L; Cheema, TA; Souders, NC; Herndon, JE; Coumans, J-V; Everitt, JI; Nahed, BV; Sampson, JH; Gunn, MD; Martuza, RL; Dranoff, G; Curry, WT; Fecci, PE, Author Correction: Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors., Nat Med, vol 25 no. 3 (2019) [10.1038/s41591-019-0355-0] [abs].
  • Suryadevara, CM; Desai, R; Farber, SH; Choi, BD; Swartz, AM; Shen, SH; Gedeon, PC; Snyder, DJ; Herndon, JE; Healy, P; Reap, EA; Archer, GE; Fecci, PE; Sampson, JH; Sanchez-Perez, L, Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts., Clinical Cancer Research, vol 25 no. 1 (2019), pp. 358-368 [10.1158/1078-0432.CCR-18-1211] [abs].
  • Natarajan, BD; Rushing, CN; Cummings, MA; Jutzy, JM; Choudhury, KR; Moravan, MJ; Fecci, PE; Adamson, J; Chmura, SJ; Milano, MT; Kirkpatrick, JP; Salama, JK, Predicting intracranial progression following stereotactic radiosurgery for brain metastases: Implications for post SRS imaging., J Radiosurg Sbrt, vol 6 no. 3 (2019), pp. 179-187 [abs].
  • Woroniecka, K; Fecci, PE, T-cell exhaustion in glioblastoma., Oncotarget, vol 9 no. 82 (2018), pp. 35287-35288 [10.18632/oncotarget.26228] [abs].
  • Atik, AF; Suryadevara, CM; Schweller, RM; West, JL; Healy, P; Herndon Ii, JE; Congdon, KL; Sanchez-Perez, L; McLendon, RE; Archer, GE; Fecci, P; Sampson, JH, Hyaluronic acid based low viscosity hydrogel as a novel carrier for Convection Enhanced Delivery of CAR T cells., J Clin Neurosci, vol 56 (2018), pp. 163-168 [10.1016/j.jocn.2018.06.005] [abs].
  • Woroniecka, K; Chongsathidkiet, P; Rhodin, K; Kemeny, H; Dechant, C; Farber, SH; Elsamadicy, AA; Cui, X; Koyama, S; Jackson, C; Hansen, LJ; Johanns, TM; Sanchez-Perez, L; Chandramohan, V; Yu, Y-RA; Bigner, DD; Giles, A; Healy, P; Dranoff, G; Weinhold, KJ; Dunn, GP; Fecci, PE, T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma., Clinical Cancer Research, vol 24 no. 17 (2018), pp. 4175-4186 [10.1158/1078-0432.CCR-17-1846] [abs].
  • Chongsathidkiet, P; Jackson, C; Koyama, S; Loebel, F; Cui, X; Farber, SH; Woroniecka, K; Elsamadicy, AA; Dechant, CA; Kemeny, HR; Sanchez-Perez, L; Cheema, TA; Souders, NC; Herndon, JE; Coumans, J-V; Everitt, JI; Nahed, BV; Sampson, JH; Gunn, MD; Martuza, RL; Dranoff, G; Curry, WT; Fecci, PE, Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors., Nat Med, vol 24 no. 9 (2018), pp. 1459-1468 [10.1038/s41591-018-0135-2] [abs].
  • Woroniecka, KI; Rhodin, KE; Chongsathidkiet, P; Keith, KA; Fecci, PE, T-cell Dysfunction in Glioblastoma: Applying a New Framework., Clinical Cancer Research, vol 24 no. 16 (2018), pp. 3792-3802 [10.1158/1078-0432.CCR-18-0047] [abs].
  • Rennert, RC; Khan, U; Tatter, SB; Field, M; Toyota, B; Fecci, PE; Judy, K; Mohammadi, AM; Landazuri, P; Sloan, A; Leuthardt, E; Chen, CC, Patterns of Clinical Use of Stereotactic Laser Ablation: Analysis of a Multicenter Prospective Registry., World Neurosurg, vol 116 (2018), pp. e566-e570 [10.1016/j.wneu.2018.05.039] [abs].
  • Giles, AJ; Hutchinson, M-KND; Sonnemann, HM; Jung, J; Fecci, PE; Ratnam, NM; Zhang, W; Song, H; Bailey, R; Davis, D; Reid, CM; Park, DM; Gilbert, MR, Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy., Journal for Immunotherapy of Cancer, vol 6 no. 1 (2018) [10.1186/s40425-018-0371-5] [abs].
  • Oldham, M; Yoon, SW; Adamson, J; Zhang, X; Fecci, P; Dewhirst, M, In Reply to Pratx and Kapp., Int J Radiat Oncol Biol Phys, vol 101 no. 2 (2018), pp. 495-496 [10.1016/j.ijrobp.2018.02.018] [abs].
  • Reap, EA; Suryadevara, CM; Batich, KA; Sanchez-Perez, L; Archer, GE; Schmittling, RJ; Norberg, PK; Herndon, JE; Healy, P; Congdon, KL; Gedeon, PC; Campbell, OC; Swartz, AM; Riccione, KA; Yi, JS; Hossain-Ibrahim, MK; Saraswathula, A; Nair, SK; Dunn-Pirio, AM; Broome, TM; Weinhold, KJ; Desjardins, A; Vlahovic, G; McLendon, RE; Friedman, AH; Friedman, HS; Bigner, DD; Fecci, PE; Mitchell, DA; Sampson, JH, Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma., Cancer Res, vol 78 no. 1 (2018), pp. 256-264 [10.1158/0008-5472.CAN-17-0469] [abs].
  • Woroniecka, K; Chongsathidkiet, P; Elsamadicy, A; Farber, H; Cui, X; Fecci, PE, Flow Cytometric Identification of Tumor-Infiltrating Lymphocytes from Glioblastoma., Methods Mol Biol, vol 1741 (2018), pp. 221-226 [10.1007/978-1-4939-7659-1_18] [abs].
  • Suryadevara, CM; Desai, R; Abel, ML; Riccione, KA; Batich, KA; Shen, SH; Chongsathidkiet, P; Gedeon, PC; Elsamadicy, AA; Snyder, DJ; Herndon, JE; Healy, P; Archer, GE; Choi, BD; Fecci, PE; Sampson, JH; Sanchez-Perez, L, Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma., Oncoimmunology, vol 7 no. 6 (2018) [10.1080/2162402X.2018.1434464] [abs].
  • Babi, M-A; Fecci, P; Luedke, M; Pineda, O; O'Keefe, YA, Atypical teratoid rhabdoid tumor in a 65-year-old man presenting with disseminated leptomeningeal disease: A case report and review of the literature., Sage Open Medical Case Reports, vol 6 (2018) [10.1177/2050313X18775298] [abs].
  • Riccione, KA; He, L-Z; Fecci, PE; Norberg, PK; Suryadevara, CM; Swartz, A; Healy, P; Reap, E; Keler, T; Li, Q-J; Congdon, KL; Sanchez-Perez, L; Sampson, JH, CD27 stimulation unveils the efficacy of linked class I/II peptide vaccines in poorly immunogenic tumors by orchestrating a coordinated CD4/CD8 T cell response., Oncoimmunology, vol 7 no. 12 (2018) [10.1080/2162402X.2018.1502904] [abs].
  • Narloch, JL; Farber, SH; Sammons, S; McSherry, F; Herndon, JE; Hoang, JK; Yin, F-F; Sampson, JH; Fecci, PE; Blackwell, KL; Kirkpatrick, JP; Kim, GJ, Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis., Neuro Oncol, vol 19 no. 10 (2017), pp. 1391-1397 [10.1093/neuonc/nox090] [abs].
  • Nayar, G; Ejikeme, T; Chongsathidkiet, P; Elsamadicy, AA; Blackwell, KL; Clarke, JM; Lad, SP; Fecci, PE, Leptomeningeal disease: current diagnostic and therapeutic strategies., Oncotarget, vol 8 no. 42 (2017), pp. 73312-73328 [10.18632/oncotarget.20272] [abs].
  • Elsamadicy, AA; Chongsathidkiet, P; Desai, R; Woroniecka, K; Farber, SH; Fecci, PE; Sampson, JH, Prospect of rindopepimut in the treatment of glioblastoma., Expert Opin Biol Ther, vol 17 no. 4 (2017), pp. 507-513 [10.1080/14712598.2017.1299705] [abs].
  • Farber, SH; Elsamadicy, AA; Atik, AF; Suryadevara, CM; Chongsathidkiet, P; Fecci, PE; Sampson, JH, The Safety of available immunotherapy for the treatment of glioblastoma., Expert Opin Drug Saf, vol 16 no. 3 (2017), pp. 277-287 [10.1080/14740338.2017.1273898] [abs].
  • Mei, Y; Bi, WL; Greenwald, NF; Du, Z; Agar, NYR; Kaiser, UB; Woodmansee, WW; Reardon, DA; Freeman, GJ; Fecci, PE; Laws, ER; Santagata, S; Dunn, GP; Dunn, IF, Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors., Oncotarget, vol 7 no. 47 (2016), pp. 76565-76576 [10.18632/oncotarget.12088] [abs].
  • Limon, D; Kim, GJ; McSherry, F; Herndon, J; Fecci, PE; Adamson, J; Sampson, JH; Floyd, SR; Wang, Z; Vlahovic, G; Yin, FF; Kirkpatrick, JP, Single-Fraction Radiosurgery for 4 or More Brain Metastases., Int J Radiat Oncol Biol Phys, vol 96 no. 2S (2016), pp. E84-E85 [10.1016/j.ijrobp.2016.06.804] [abs].
  • Suryadevara, CM; Desai, R; Farber, SH; Gedeon, PC; Swartz, A; Snyder, D; Herndon, J; Healy, P; Choi, BD; Fecci, PE; Sanchez-Perez, L; Sampson, JH, 369 Chimeric Antigen Receptors Deficient in Lck Signaling Require 4-1BB Costimulation to Expand in Vivo, Resist Regulatory T-Cell Suppression, and Treat Solid Tumors in Immune-Intact Hosts., Neurosurgery, vol 63 no. CN_suppl_1 (2016), pp. 209-210 [10.1227/01.neu.0000489857.70440.98] [abs].
  • Suryadevara, CM; Desai, R; Farber, SH; Gedeon, PC; Swartz, A; Snyder, D; Herndon, J; Healy, P; Choi, BD; Fecci, PE; Sanchez-Perez, L; Sampson, JH, 369 Chimeric Antigen Receptors Deficient in Lck Signaling Require 4-1BB Costimulation to Expand in Vivo, Resist Regulatory T-Cell Suppression, and Treat Solid Tumors in Immune-Intact Hosts., Neurosurgery, vol 63 Suppl 1 (2016), pp. 209-210 [10.1227/01.neu.0000489857.70440.98] [abs].
  • Farber, SH; Tsvankin, V; Narloch, JL; Kim, GJ; Salama, AKS; Vlahovic, G; Blackwell, KL; Kirkpatrick, JP; Fecci, PE, Embracing rejection: Immunologic trends in brain metastasis., Oncoimmunology, vol 5 no. 7 (2016) [10.1080/2162402X.2016.1172153] [abs].
  • Koyama, S; Akbay, EA; Li, YY; Aref, AR; Skoulidis, F; Herter-Sprie, GS; Buczkowski, KA; Liu, Y; Awad, MM; Denning, WL; Diao, L; Wang, J; Parra-Cuentas, ER; Wistuba, II; Soucheray, M; Thai, T; Asahina, H; Kitajima, S; Altabef, A; Cavanaugh, JD; Rhee, K; Gao, P; Zhang, H; Fecci, PE; Shimamura, T; Hellmann, MD; Heymach, JV; Hodi, FS; Freeman, GJ; Barbie, DA; Dranoff, G; Hammerman, PS; Wong, K-K, STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment., Cancer Res, vol 76 no. 5 (2016), pp. 999-1008 [10.1158/0008-5472.CAN-15-1439] [abs].
  • Koyama, S; Akbay, EA; Li, YY; Herter-Sprie, GS; Buczkowski, KA; Richards, WG; Gandhi, L; Redig, AJ; Rodig, SJ; Asahina, H; Jones, RE; Kulkarni, MM; Kuraguchi, M; Palakurthi, S; Fecci, PE; Johnson, BE; Janne, PA; Engelman, JA; Gangadharan, SP; Costa, DB; Freeman, GJ; Bueno, R; Hodi, FS; Dranoff, G; Wong, K-K; Hammerman, PS, Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints., Nature Communications, vol 7 (2016) [10.1038/ncomms10501] [abs].
  • Choi, BD; Fecci, PE; Sampson, JH, Editorial: Not everything that matters can be measured and not everything that can be measured matters., J Neurosurg, vol 123 no. 3 (2015), pp. 543-544 [10.3171/2015.2.JNS142977] [abs].
  • Vlahovic, G; Fecci, PE; Reardon, D; Sampson, JH, Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma., Neuro Oncol, vol 17 no. 8 (2015), pp. 1043-1045 [10.1093/neuonc/nov071] [abs].
  • Swartz, AM; Batich, KA; Fecci, PE; Sampson, JH, Peptide vaccines for the treatment of glioblastoma., J Neurooncol, vol 123 no. 3 (2015), pp. 433-440 [10.1007/s11060-014-1676-y] [abs].
  • Fecci, PE; Babu, R; Adamson, DC; Sampson, JH, Editorial: Turning fluorescence into black and white., J Neurosurg, vol 122 no. 6 (2015), pp. 1356-1358 [10.3171/2014.10.JNS141788] [abs].
  • Suryadevara, CM; Gedeon, PC; Sanchez-Perez, L; Verla, T; Alvarez-Breckenridge, C; Choi, BD; Fecci, PE; Sampson, JH, Are BiTEs the "missing link" in cancer therapy?, Oncoimmunology, vol 4 no. 6 (2015) [10.1080/2162402X.2015.1008339] [abs].
  • Suryadevara, CM; Verla, T; Sanchez-Perez, L; Reap, EA; Choi, BD; Fecci, PE; Sampson, JH, Immunotherapy for malignant glioma., Surgical Neurology International, vol 6 no. Suppl 1 (2015), pp. S68-S77 [10.4103/2152-7806.151341] [abs].
  • Fecci, PE; Heimberger, AB; Sampson, JH, Immunotherapy for primary brain tumors: no longer a matter of privilege., Clinical Cancer Research, vol 20 no. 22 (2014), pp. 5620-5629 [10.1158/1078-0432.CCR-14-0832] [abs].
  • Yanamadala, V; Walcott, BP; Fecci, PE; Rozman, P; Kumar, JI; Nahed, BV; Swearingen, B, Reversal of warfarin associated coagulopathy with 4-factor prothrombin complex concentrate in traumatic brain injury and intracranial hemorrhage., J Clin Neurosci, vol 21 no. 11 (2014), pp. 1881-1884 [10.1016/j.jocn.2014.05.001] [abs].
  • Gedeon, PC; Riccione, KA; Fecci, PE; Sampson, JH, Antibody-based immunotherapy for malignant glioma., Semin Oncol, vol 41 no. 4 (2014), pp. 496-510 [10.1053/j.seminoncol.2014.06.004] [abs].
  • Cheema, TA; Fecci, PE; Ning, J; Rabkin, SD, Immunovirotherapy for the treatment of glioblastoma., Oncoimmunology, vol 3 no. 1 (2014) [10.4161/onci.27218] [abs].
  • Akbay, EA; Koyama, S; Carretero, J; Altabef, A; Tchaicha, JH; Christensen, CL; Mikse, OR; Cherniack, AD; Beauchamp, EM; Pugh, TJ; Wilkerson, MD; Fecci, PE; Butaney, M; Reibel, JB; Soucheray, M; Cohoon, TJ; Janne, PA; Meyerson, M; Hayes, DN; Shapiro, GI; Shimamura, T; Sholl, LM; Rodig, SJ; Freeman, GJ; Hammerman, PS; Dranoff, G; Wong, K-K, Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors., Cancer Discov, vol 3 no. 12 (2013), pp. 1355-1363 [10.1158/2159-8290.CD-13-0310] [abs].
  • Cheema, TA; Wakimoto, H; Fecci, PE; Ning, J; Kuroda, T; Jeyaretna, DS; Martuza, RL; Rabkin, SD, Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model., Proc Natl Acad Sci U S A, vol 110 no. 29 (2013), pp. 12006-12011 [10.1073/pnas.1307935110] [abs].
  • Reardon, DA; Wucherpfennig, KW; Freeman, G; Wu, CJ; Chiocca, EA; Wen, PY; Curry, WT; Mitchell, DA; Fecci, PE; Sampson, JH; Dranoff, G, An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma., Expert Rev Vaccines, vol 12 no. 6 (2013), pp. 597-615 [10.1586/erv.13.41] [abs].
  • Choi, BD; Fecci, PE; Sampson, JH, Regulatory T cells move in when gliomas say "I Do"., Clinical Cancer Research, vol 18 no. 22 (2012), pp. 6086-6088 [10.1158/1078-0432.CCR-12-2801] [abs].
  • Dunn, GP; Fecci, PE; Curry, WT, Cancer immunoediting in malignant glioma., Neurosurgery, vol 71 no. 2 (2012), pp. 201-222 [10.1227/NEU.0b013e31824f840d] [abs].
  • Agarwalla, P; Barnard, Z; Fecci, P; Dranoff, G; Curry, WT, Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors., J Immunother, vol 35 no. 5 (2012), pp. 385-389 [10.1097/CJI.0b013e3182562d59] [abs].
  • Chatterjee, N; Domoto-Reilly, K; Fecci, PE; Schwamm, LH; Singhal, AB, Licorice-associated reversible cerebral vasoconstriction with PRES., Neurology, vol 75 no. 21 (2010), pp. 1939-1941 [10.1212/WNL.0b013e3181feb299] [abs].
  • Fecci, PE; Ochiai, H; Mitchell, DA; Grossi, PM; Sweeney, AE; Archer, GE; Cummings, T; Allison, JP; Bigner, DD; Sampson, JH, Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function., Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, vol 13 no. 7 (2007), pp. 2158-2167 [10.1158/1078-0432.CCR-06-2070] [abs].
  • Fecci, PE; Sweeney, AE; Grossi, PM; Nair, SK; Learn, CA; Mitchell, DA; Cui, X; Cummings, TJ; Bigner, DD; Gilboa, E; Sampson, JH, Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells., Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, vol 12 no. 14 Pt 1 (2006), pp. 4294-4305 [10.1158/1078-0432.CCR-06-0053] [abs].
  • Fecci, PE; Mitchell, DA; Whitesides, JF; Xie, W; Friedman, AH; Archer, GE; Herndon, JE; Bigner, DD; Dranoff, G; Sampson, JH, Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma., Cancer Research, vol 66 no. 6 (2006), pp. 3294-3302 [10.1158/0008-5472.CAN-05-3773] [abs].